Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.

Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.

On 7th July 2021, the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte – BfArM) launched the first sale of cannabis exclusively for medical purposes from cultivation in Germany. Pharmacies are now able to purchase medical cannabis flowers of pharmaceutical drug quality for the supply of patients from the BfArM via the official portal of the German Cannabis Agency (www.cannabisagentur.de).

Lotta Ferm, interim CFO of Immunicum AB, was now named as Chief Financial Officer.

Pfizer Inc announced it will  allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.

London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.

The COVID-19 pandemic created exceptional circumstances for virologists. To speed up the process from initial basic experiments to the final clinical application, appropriate reagents are required. Isolation of SARS-CoV-2-specific T cells via the MHC Streptamer® approach yields label-free, fully functional cells, making this method a valuable tool for high quality research.

BIAL, a public limited company under Portuguese law with head office in Coronado, Portugal, appointed Joerg Holenz as R&D General Manager and as a member of the Board of Directors.

The EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.

By applying the expertise, best practice, and emerging technologies of the logistics industry,  biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.